SCHEMBL2534809

SCHEMBL2534809

O=C(O)C=Cc1cc(Br)ccc1OCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.49
PPARG P37231 1/20 0.49
PTGER4 P35408 3/20 0.47
PTGER2 P43116 3/20 0.47
PTGER3 P43115 3/20 0.47
LTB4R Q15722 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
CCR5 P51681 6/20 0.45
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534806 1.00 PTGER1 (0.49) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2538769 0.88 PPARG (0.49) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2538771 0.88 PPARG (0.49) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL13764924 0.87 PTGER4 (0.50) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2536635 0.85 PTGER4 (0.51) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2532399 0.85 PTGER4 (0.51) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2536639 0.85 PTGER4 (0.51) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2532401 0.85 PTGER4 (0.51) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2534788 0.84 PPARG (0.55) PTGER1PPARGPTGER4PTGER2PTGER3
SCHEMBL2534786 0.84 PPARG (0.55) PTGER1PPARGPTGER4PTGER2PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 PTGER1 905/4885PPARG 818/4885PTGER4 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.